Immupharma PLC Enterprise Investment Scheme Status (1727D)
January 27 2015 - 2:01AM
UK Regulatory
TIDMIMM
RNS Number : 1727D
Immupharma PLC
27 January 2015
FOR IMMEDIATE RELEASE: FULL RNS 27 JANUARY 2015
IMMUPHARMA
Advance Assurance Received from H M Revenue and Customs
Regarding
"Enterprise Investment Scheme" Status
ImmuPharma PLC (AIM: IMM) ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, announces that
it has received advance assurance from H M Revenue and Customs that
it would qualify for Enterprise Investment Scheme (EIS) status.
EIS offers a range of tax reliefs to investors who invest in
qualifying companies. These tax reliefs would be available provided
that the individual and the Company continue to meet the rules of
the Scheme at the time of the investment and for a period of 3
years subsequently.
Commenting on the agreement, Richard Warr, ImmuPharma's
Executive Chairman, said: "We are pleased to have received this
advanced assurance from HM Revenue and Customs. Qualifying for EIS
gives ImmuPharma access to the broadest range of potential
investors and investment funds."
ENDS
For further information please contact:
+ 44 (0) 20 7152
ImmuPharma plc 4080
Dimitri Dimitriou, Chief Executive
Officer
Dr Robert Zimmer, President
and Chief Scientific Officer
Richard Warr, Chairman
Tracy Weimar, Vice President,
Operations and Finance
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721 413496
Panmure, Gordon & Co., NOMAD
& Broker +44 (0) 20 7886 2500
Hugh Morgan
Fred Walsh
Duncan Monteith
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAXFKADSSEFF
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024